The 3-year survival data strongly de-risks RP1's regulatory path in anti-PD-1-failed melanoma, a setting with limited options. Traders should watch for FDA BLA acceptance and potential priority review, which could drive further upside. The data also supports expansion into earlier lines and combination trials.
REPL drugs
REPL drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $9.00entry
- T+1 · 6mo ago −1.44%α −1.59% · $8.87
- T+5 · 5mo ago +5.22%α +7.97% · $9.47
- T+20 · 5mo ago +23.00%α +24.30% · $11.07
- T+60 · 3mo ago +75.56%α +74.32% · $15.80
Price Chart
How similar events traded
Executive Summary
Replimune presented 3-year landmark overall survival data from the IGNYTE trial of RP1 plus nivolumab in anti-PD-1-failed melanoma at ASCO 2026. The data showed a median overall survival of 32.9 months, with 47.8% of all treated patients alive at 3 years and 83.5% of responders alive at 3 years. This is a highly positive clinical data readout for a clinical-stage biotech with a single lead asset, providing strong evidence of durable benefit in a difficult-to-treat population.
Key Facts
- Median overall survival (mOS) of 32.9 months in anti-PD-1-failed advanced melanoma patients treated with RP1 plus nivolumab.
- 47.8% of all treated patients alive at 3 years; 83.5% of responders alive at 3 years.
- Objective response rate (ORR) of 33.6% with median duration of response (DOR) of 24.8 months; 44.8% of responders maintained response at 3 years.
- Favorable safety profile with no Grade 5 events and no new safety signals over long-term follow-up.
- Data presented at ASCO 2026 oral session (Abstract 9518).
Financial Impact
Transformative for a clinical-stage biotech with a single lead asset; positive survival data in a high-need indication could support BLA approval and significant commercial upside.
Risk Factors
- BLA review outcome remains uncertain; FDA may request additional data or raise concerns.
- Competition from other oncolytic viruses and combination immunotherapies could limit market share.
- Clinical-stage company with no approved products; cash burn and dilution risk remain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303875 |
Track record
32 reports on REPL
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers